Synopsis:
The stock gained after posting a strong Q2FY26 performance with 20% revenue growth and a 392% surge in profit. Robust biosimilar and generics growth, improved margins, debt reduction, and global recognition for innovation and governance strengthened investor confidence in its long-term growth potential.
The shares of the biopharmaceutical company rose up to 3 percent in today’s trading session after the company’s net profit and revenue jumped 392 percent and 20 percent in Q2FY26, respectively.
With a market capitalization of Rs 51,780.60 crore, the shares of Biocon Ltd were trading at Rs 387.00 per share, increasing around 0.49 percent as compared to the previous closing price of Rs 385.10 apiece.
Q2FY26 Highlights
The shares of Biocon Ltd have seen positive movement after announcing its financial performance in Q2FY26, in which revenue increased by 20 percent on a year-on-year basis from Rs 3,590 crore in Q2FY25 to Rs 4,296 crore in Q2FY26. However, on a Quarter-on-Quarter basis, revenue zoomed by 9 percent from Rs 3,942 crore in Q1FY26 to Rs 4,296 crore in Q2FY26.
Moreover, net profit increased by 392 percent on a yearly basis from Rs 27 crore in Q2FY25 to Rs 133 crore in Q2FY26, meanwhile, on a quarter-on-quarter basis, net profit jumped by 49 percent from Rs 89 crore in Q1FY26 to Rs 133 crore in Q2FY26.
Additionally, the company delivered a strong Q2FY26 performance supported by solid growth in Biosimilars and improved traction in Generics. The CRDMO segment provided steady support, while EBITDA surged 29% to Rs 928 crore, reflecting better operating leverage and cost efficiency across business segments.
Biocon Limited is a leading global biopharmaceutical company based in Bengaluru, India, specializing in innovative and affordable healthcare solutions. The company focuses on biosimilars, generics, and research services, aiming to make advanced therapies accessible worldwide while driving sustainable growth through scientific excellence, innovation, and strong global partnerships.
The company reported strong growth across key segments in Q2FY26, with Biosimilars revenue rising 25% year-on-year to Rs 2,721 crore and Generics up 24% to Rs 774 crore. The CRDMO/Research Services segment remained stable, growing 2% to Rs 911 crore, reflecting consistent performance across diversified business verticals.
The company strengthened its balance sheet by reducing debt through QIP proceeds and refinancing, targeting Rs 300 crore in annual interest savings from FY27. It achieved US FDA approval for bDenosumab, partnered with California for affordable Insulin Glargine, and earned recognition for sustainability and governance excellence through global awards and improved ESG scores.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
